Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Autor: Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Tayob N; Harvard Medical School, Boston, MA.; Division of Data Science, Dana-Farber Cancer Institute, Boston, MA., Villacampa G; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Oncology Data Science Vall d'Hebron Institute of Oncology, Barcelona, Spain., Dang C; Memorial Sloan Kettering Cancer Center, New York, NY., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN., Isakoff SJ; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Valero V; MD Anderson Cancer Center, Houston, TX., Faggen M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Mulvey T; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Bose R; Washington University School of Medicine, St Louis, MO., Weckstein D; New Hampshire Oncology Hematology, Manchester, NH., Wolff AC; Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC., Reeder-Hayes K; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Rugo HS; University of California, San Francisco, CA., Ramaswamy B; Ohio State University Comprehensive Cancer Center, Columbus, OH., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, ID., Hart L; Wake Forest Baptist Health, Winston-Salem, NC., Gadi VK; University of Illinois Cancer Center, Chicago, IL., Constantine M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Cheng K; North Shore-LIJ Cancer Institute, Lake Success, NY., Garrett AM; Northern Light Cancer Care, Brewer, ME., Marcom PK; Duke University School of Medicine, Durham, NC., Albain K; Loyola University Medical Center, Maywood, IL., DeFusco P; Hartford Healthcare Cancer Institute, Hartford, CT., Tung N; Harvard Medical School, Boston, MA.; Beth Israel Deaconess Medical Center, Boston, MA., Ardman B; Lowell General Hospital, Lowell, MA., Nanda R; UChicago Medicine, Chicago, IL., Jankowitz RC; Perelman Center for Advanced Medicine, Philadelphia, PA., Rimawi M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Abramson V; Vanderbilt-Ingram Cancer Center, Nashville, TN., Pohlmann PR; MD Anderson Cancer Center, Houston, TX.; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC., Van Poznak C; Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Forero-Torres A; Kirklin UAB Hematology Oncology, Birmingham, AL., Liu MC; Natera, Inc, Austin, TX., Ruddy KJ; Mayo Clinic, Rochester, NY., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., DeMeo M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Burstein HJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Dell'Orto P; IEO European Institute of Oncology, IRCCS, Milan, Italy., Russo L; IEO European Institute of Oncology, IRCCS, Milan, Italy., Krause E; PathAI, Boston, MA., Newhouse DJ; NanoString Technologies, Inc, Boston, MA., Kurt BB; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA., Schneider B; Indiana University School of Medicine, Indianapolis, IN., Prat A; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Nov; Vol. 42 (31), pp. 3652-3665. Date of Electronic Publication: 2024 Jun 27.

γ-Protocadherins control synapse formation and peripheral branching of touch sensory neurons.

Autor: Meltzer S; Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115, USA., Boulanger KC; Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115, USA., Chirila AM; Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115, USA., Osei-Asante E; Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115, USA., DeLisle M; Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115, USA., Zhang Q; Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115, USA., Kalish BT; Department of Neurobiology, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115, USA., Tasnim A; Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115, USA., Huey EL; Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115, USA., Fuller LC; Department of Biology and Iowa Neuroscience Institute, University of Iowa, 143 Biology Building, Iowa City, IA 52242, USA., Flaherty EK; Department of Biochemistry and Molecular Biophysics, Zuckerman Institute of Mind Brain and Behavior, Columbia University, New York, NY 10032, USA., Maniatis T; Department of Biochemistry and Molecular Biophysics, Zuckerman Institute of Mind Brain and Behavior, Columbia University, New York, NY 10032, USA., Garrett AM; Department of Pharmacology and Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, 540 E. Canfield St. 7322 Scott Hall, Detroit, MI 48201, USA., Weiner JA; Department of Biology and Iowa Neuroscience Institute, University of Iowa, 143 Biology Building, Iowa City, IA 52242, USA., Ginty DD; Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115, USA. Electronic address: david_ginty@hms.harvard.edu.

Publikováno v: Neuron [Neuron] 2023 Jun 07; Vol. 111 (11), pp. 1776-1794.e10. Date of Electronic Publication: 2023 Apr 06.